Skip to content

Study · Systematic review · n = 878 · 2025

8 results

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.

Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM

Proceedings (Baylor University. Medical Center)5 Feb 2025Cited by 16 (Europe PMC)

PMID40291085 (opens in a new tab)PMCIDPMC12026077 (opens in a new tab)DOI10.1080/08998280.2025.2456441 (opens in a new tab)PepBankPUB-40291085
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced body weight versus placebo (mean difference -14.33%, P < 0.00001).

    In plain wordsIn people with obesity, retatrutide lowered body weight more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight change
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference body weight
    −14.33%
    retatrutide vs placebo

    Source sentences

    Summary
    Retatrutide significantly reduced body weight (mean difference [MD]: -14.33%)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced body mass index versus placebo (mean difference -5.38).

    In plain wordsIn people with obesity, retatrutide lowered body mass index more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody mass index
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference BMI
    −5.38
    retatrutide vs placebo

    Source sentences

    Summary
    body mass index (MD: -5.38)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced waist circumference versus placebo (mean difference -10.51 cm).

    In plain wordsIn people with obesity, retatrutide shrank waist size more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference waist circumference
    −10.51 cm
    retatrutide vs placebo

    Source sentences

    Summary
    waist circumference (MD: -10.51 cm)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced fasting plasma glucose versus placebo (mean difference -23.51 mg/dL).

    In plain wordsIn people with obesity, retatrutide lowered fasting blood sugar more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference fasting plasma glucose
    −23.51 mg/dL
    retatrutide vs placebo

    Source sentences

    Summary
    fasting plasma glucose (MD: -23.51 mg/dL)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced hemoglobin A1c versus placebo (mean difference -0.91%).

    In plain wordsIn people with obesity, retatrutide lowered HbA1c more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseHemoglobin A1c
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference HbA1c
    −0.91%
    retatrutide vs placebo

    Source sentences

    Summary
    hemoglobin A1c (MD: -0.91%)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  6. 06HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced systolic blood pressure versus placebo (mean difference -9.88 mm Hg).

    In plain wordsIn people with obesity, retatrutide lowered systolic blood pressure more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference systolic blood pressure
    −9.88 mm Hg
    retatrutide vs placebo

    Source sentences

    Summary
    systolic and diastolic blood pressure (MD: -9.88 mm Hg and -3.88 mm Hg, respectively)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  7. 07HumanSystematic reviewEfficacy outcome

    In a meta-analysis of three randomized trials in obese patients, retatrutide reduced diastolic blood pressure versus placebo (mean difference -3.88 mm Hg).

    In plain wordsIn people with obesity, retatrutide lowered diastolic blood pressure more than placebo across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference diastolic blood pressure
    −3.88 mm Hg
    retatrutide vs placebo

    Source sentences

    Summary
    systolic and diastolic blood pressure (MD: -9.88 mm Hg and -3.88 mm Hg, respectively)
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.
  8. 08HumanSystematic reviewSafety outcome

    In a meta-analysis of three randomized trials in obese patients, adverse events did not differ significantly between retatrutide and placebo (relative risk 1.11, P = 0.24).

    In plain wordsIn people with obesity, retatrutide and placebo groups had no significant difference in adverse events across three pooled trials.

    Peptide
    Retatrutide
    Outcome
    No significant changeAdverse events (any)
    Study

    n = 878

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    Relative risk adverse events
    1.11
    retatrutide vs placebo

    Source sentences

    Summary
    No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24).
    2 context sentences
    Summary · context
    Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients.
    Summary · context
    Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.